Expanded-Access Program for the Treatment of Chronic Hepatitis D With Brelovitug

This expanded access program provides brelovitug at no cost to eligible adults with chronic hepatitis D who have no comparable approved treatment option, cannot tolerate or continue approved therapy, or are not candidates for approved therapy based on the treating physician's clinical judgment. Patients must be unable or ineligible to participate in an available brelovitug clinical trial. All patients must meet the following criteria to be considered eligible for program entry: 1. Informed consent and assent provided, as applicable per Institutional Review Board (IRB) / Ethic Committee (EC), and willing to comply with the procedures and assessments. 2. Medical diagnosis of Chronic Hepatitis Delta with confirmatory hepatitis delta virus (HDV) antibody and RNA 3. On stable nucleos(t)ide therapy for Chronic Hepatitis B for duration of EAP and after EAP at direction of treating physician. 4. Patients aged ≥18 years for whom, in the judgment of the treating physician, treatment with brelovitug is clinically appropriate based on efficacy, safety, or other relevant clinical considerations. * Patients who are intolerant, non-compliant, ineligible or who discontinue a currently approved therapy; or patients who are not candidates for a currently approved therapy in the clinical judgment of the treating physician.